Genmab and Pepscan in Research Collaboration

Genmab A/S and Pepscan Therapeutics have announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets. Intractable targets include those that are difficult to address using commonly available technologies but are highly desirable for targeting with monoclonal antibodies. These difficulties can for example be due to the fact that target proteins are buried to a large extent very close to the cell surface or in the cell membrane or due to poor immunogenicity of the protein or desirable epitopes.

In the collaboration, Pepscan will use its proprietary CLIPS technology to identify functional mimics of the essential parts of such intractable targets. These mimics will be used by Genmab to create and select unique therapeutic antibodies, using its fully human monoclonal antibody technology.

For further information please contact:

Helle Husted,

Director Investor Relations

Tel: +45 33 44 77 30

Email: hth@genmab.com

Or visit: www.genmab.com